# US 2016/0256564 A2 · Photosensitizing antibody-fluorophore conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256564 A2
- Document ID: US20160256564A2
- Status: Published application
- Kind: A2
- Application number: 14/868,040
- Filed: 2015-09-28
- Published: 2016-09-08
- Earliest claimed: 2010-07-09
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Hisataka Kobayashi; Peter Choyke
- Web page: https://patentgrep.com/patent/US20160256564A2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0036: {Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546)}
- A61K 49/0058: {Antibodies}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/32: against translation products of oncogenes
- G01N 33/5011: {for testing antineoplastic activity}
- A41D 13/0002: {Details of protective garments not provided for in groups A41D13/0007 - A41D13/1281}
- A41D 2400/32: Therapeutic use
- A44C 15/00: Other forms of jewellery
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A41D: OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A44C: PERSONAL ADORNMENTS, e.g. JEWELLERY; COINS

## Abstract

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

## Claims

### Claim 1

A phototoxic pharmaceutical composition for treating a tumor, comprising:
a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds HER1; and
a pharmaceutical carrier, wherein the phototoxic conjugate exhibits phototoxicity to kill tumor cells.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is selected from the group consisting of cetuximab, panitumumab, zalutumumab, nimotuzumab and matuzumab, or an antigen binding fragment thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is cetuximab.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is panitumumab.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is zalutumumab.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is nimotuzumab.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antibody is matuzumab.

### Claim 8

A combination, comprising:
a first composition comprising a phototoxic conjugate comprising an IR700 molecule conjugated to an antibody that binds HER1; and
a second composition comprising an additional therapeutic agent.

### Claim 9 (depends on 8)

The combination of claim 8, wherein the first and/or second composition comprise a pharmaceutically acceptable carrier.

### Claim 10 (depends on 8)

The combination of claim 8, wherein the antibody is selected from the group consisting of cetuximab, panitumumab, zalutumumab, nimotuzumab and matuzumab, or an antigen binding fragment thereof.

### Claim 11 (depends on 8)

The combination of claim 8, wherein the antibody is cetuximab.

### Claim 12 (depends on 8)

The combination of claim 8, wherein the antibody is panitumumab.

### Claim 13 (depends on 8)

The combination of claim 8, wherein the antibody is zalutumumab.

### Claim 14 (depends on 8)

The combination of claim 8, wherein the antibody is nimotuzumab.

### Claim 15 (depends on 8)

The combination of claim 8, wherein the antibody is matuzumab.

### Claim 16 (depends on 8)

The combination of claim 8, wherein the first and second composition are formulated separately.

### Claim 17 (depends on 8)

The combination of claim 8, wherein the therapeutic agent is an anti-cancer or anti-neoplastic agent.

### Claim 18 (depends on 8)

The combination of claim 8, wherein the therapeutic agent is selected from the group consisting of a radiotherapeutic agent, a chemotherapeutic agent, an antibiotic, an alkylating agent, an antioxidant and a kinase inhibitor.

### Claim 19 (depends on 8)

The combination of claim 8, wherein the therapeutic agent is selected from among a microtubule binding agent, a DNA intercalator or cross-linker, a DNA synthesis inhibitor, a DNA or RNA transcription inhibitor, an antibody, an enzyme, an enzyme inhibitor and a compound that affects gene regulation.

### Claim 20 (depends on 8)

The combination of claim 8, wherein the therapeutic agent is selected from among paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine, epothilone, colchicine, dolastatin 15, nocodazole, podophyllotoxin, rhizoxin, actinomycin D, daunorubicin, cisplatin, carboplatin, oxaliplatin, mitomycin C, bleomycin, chlorambucil, cyclophosphamide, methotrexate, 5-fluro-5′-deoxyuridine, 5-fluorouracil, camptothecin, etoposide, formestane, trichostatin, raloxifene, 5-azacytidine, 5-aza-2′-deoxycytidine, tamoxifen, 4-hydroxytamoxifen, mifepristone, Gleevac, Iressa, Tarceva, adriamycine, apigenin, rapamycine, zebularine, cimetidine, interleukin-2 (IL-2), and an anti-CTLA4 antibody or analogs or derivatives thereof.
